Natera's Signatera Test Predicts Survival Benefit from Chemotherapy in Metastatic Colorectal Cancer
Event summary
- Natera's Signatera MRD test demonstrated that adjuvant chemotherapy (ACT) improved overall survival (OS) in MRD-positive patients with resected colorectal liver metastases.
- The study, published in JAMA Oncology and presented at the 2026 ESMO GI Congress, included 298 patients from the GALAXY trial with a median follow-up of 43 months.
- MRD-positive patients who received ACT had a 48-month OS rate of 65.3% compared to 32.9% for those under observation (adjusted HR, 0.27; P=0.03).
- Post-surgical MRD positivity was strongly prognostic, with significantly worse DFS and OS outcomes regardless of neoadjuvant chemotherapy status.
The big picture
Natera's data challenges the historical uncertainty around adjuvant chemotherapy in resected colorectal liver metastases, positioning Signatera as a potential decision-making tool. The findings align with broader trends in precision oncology, where molecular residual disease testing is increasingly used to personalize treatment strategies. This could expand Natera's market opportunity in an oncology space dominated by larger diagnostics players.
What we're watching
- Clinical Adoption
- How quickly oncologists will integrate Signatera's MRD testing into standard care for colorectal liver metastases.
- Reimbursement Dynamics
- Whether payers will expand coverage for Signatera based on these survival benefit findings.
- Competitive Positioning
- The pace at which Natera can differentiate Signatera from emerging MRD testing alternatives in oncology.
Related topics